Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Small Molecules Studied

HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10097-3 Erlotinib
OSI-774
 LSM-1097 176870
10281-1 Vinorelbine
Navelbine
 LSM-6302 5311497
10265-1 Pevonedistat
MLN 4924; MLN-4924; MLN4924
 LSM-6263 16720766
10348-1 Z-Leu-Leu-Norvalinal
MG-115
 LSM-6358 9868928
10062-3 GSK1070916
KIN001-216
 LSM-1062 46885626
10035-2 Sigma A6730
KIN001-102; AKT inhibitor VIII; Akt1/2 kinase inhibitor
 LSM-1035 10196499
10246-1 CPT-11
Irinotecan
 LSM-2167 60838
10278-1 Topotecan
Hycamtin
 LSM-5662 60700
10051-3 Lapatinib
GW-572016; Tykerb
 LSM-1051 208908
10013-3 GSK461364
GSK461364A
 LSM-1013 15983966
10146-2 Omipalisib
GSK2126458; GSK2126458A
 LSM-1147 25167777
10142-2 Trametinib
GSK-1120212; GSK1120212; GSK1120212B; JTP-74057
 LSM-1143 11707110
10023-3 Imatinib
Gleevec; Glivec; CGP-57148B; STI-571
 LSM-1023 5291
10252-1 Gemcitabine
Gemzar
 LSM-5333 60750
10110-3 FR180204
FR 180204; KIN001-230
 LSM-42790 11493598
10238-1 5-FU
Fluorouracil
 LSM-4261 3385
10269-1 Oxaliplatin
Eloxatin
 LSM-44941 5310940
10249-1 Epirubicin
Ellence
 LSM-2078 41867
10346-1 Valproic acid
Depakine
 LSM-4620 3549980
10048 PD184352
CI-1040
 LSM-1048 6918454
10048-6 PD184352
CI-1040
 LSM-1048 6918454
10048-7 PD184352
CI-1040
 LSM-1048 6918454
10230-2 Lestaurtinib
CEP-701
 LSM-1231 126565
10245-1 Cisplatin
CDDP; cis-Diaminodichloroplatinum; Cisplatinum; Lederplatin; Briplatin; Cismaplat
 LSM-4268
10258-1 Ibandronate
Boniva
 LSM-4279 44828485